Web portal for stock market traders

Dendreon Corp. (NASDAQ: DNDN) was all over the map last year, is their pipeline for real or hype?

What do you reckon on from them in 2008?

52wk Range: 3.57 - 25.25

http://finance.yahoo.com/q?s=dndn


I never saw it at 25...but it was in the lofty teens for awhile...it definitely was overpriced there.
According to a couple of Fast Money guys, it does have a expected ... real products and takeover possibilities... 6 or 7 could be a nice price....could


I never saw it at 25...but it was in the high teens for awhile...it decidedly was overpriced there.
According to a couple of Fast Money guys, it does have a future ... real products and takeover possibilities... 6 or 7 could be a discriminating price....could

News Update: Dendreon (NASDAQ:DNDN) Jumps on Provenge Prostate Treatment Success

3/4/2010-Shares of Dendreon (NASDAQ:DNDN) are trading 3.9% higher to $34.94 Thursday after the anaesthetize developer said yesterday that its experimental ...

News Update: Dendreon (NASDAQ:DNDN) Up 1213.5% in One Year

Dendreontraded in a distance yesterday that spanned from a low of $39.65 to a high of $54.58. Yesterday's high of the day pierced the 3-day high ...

NASDAQ Stocks Ended Higher (CELG, DNDN, ILMN, ARIA) | MBPE Capital

Dendreon Corporation is a biotechnology performers focused on the finding, evolution and commercialization of therapeutics that may rally cancer treatment options for patients.

...

Read more...

NASDAQ Stocks Ended Lower (AMGN, CELG, GENZ, DNDN) | MBPE Capital

Celgene Corporation is an integrated biopharmaceutical concern pre-eminently plighted in the uncovering, advance and commercialization of therapies designed to study cancer and inoculated-traitorous agnate diseases.

...

Read more...

NASDAQ Stocks Ended Higher (CTIC, CELG, AMGN, DNDN) | MBPE Capital

Celgene Corporation is an integrated biopharmaceutical performers in the first instance wrapped up in the ascertaining, increment and commercialization of therapies designed to care of cancer and unsusceptible-seditious correlated diseases.

...

Read more...

DNDN (NASDAQ:DNDN) Reports Earnings: A Stellar Stock Story, Plenty ...

That said, Provenge sales increased from $20 to $24 million section-over-clemency, although losses also grew significantly, but again, that is in the long run attributed to bringing the manufacturing plants on path.

...

Read more...

Top 10 Mid-Cap Stocks with Highest Upside: LEA, BCA, AGO, DNDN ...

Lear Corporation (NYSE:LEA) has the 1st highest upside future in this subdivide of the sell. Its upside is 116.1%. Its consensus butt sacrifice is $105.97 based...

Read more...

Nasdaq Dndn - News


Dendreon Announces Data Presentation at the 2012 American Urological ...
SEATTLE, May 21, 2012 (Dealing WIRE) -- May 21, 2012--Dendreon Corporation (NASDAQ:DNDN) today announced the following PROVENGE(R) (sipuleucel-T) matter will be presented at the American Urological Association (AUA) Annual Meeting taking place May 19

Investment Analysts' Ratings Reiterations for May, 23rd (ADI, AVGO, AZO, DELL ...
Dell Inc. (NASDAQ: DELL) had its “parallel weight” rating re-affirmed by analysts at Morgan Stanley. They now have a $16.00 price target on the stockpile, down previously from $18.00. Dendreon Co. (NASDAQ: DNDN) had its “hold” rating re-affirmed by analysts

Rival Drug Approval Put Back to Dendreon (NASDAQ:DNDN) Shares Around 5%- DNDN ...
Shares in Dendreon Corporation (NASDAQ:DNDN) dropped over 4.97% in last trading day, and reasons could cover a SEC investigation into the Seattle biotech and the victory of a competitor's prostate cancer drug. In Friday trading, Dendreon shares were



Leave a Reply